Aetna chairman Ron Williams to retire, Mark T. Bertolini to become CEO
Aetna Chairman and CEO Ronald A. Williams will retire from Aetna in April 2011. On Nov. 29, 2010, Mark T. Bertolini will be appointed chief executive officer and elected to the company?s Board of Directors.
Aetna Chairman and CEO Ronald A. Williams, 60, will retire from Aetna in April 2011. On Nov. 29, 2010, Williams will become executive chairman and Mark T. Bertolini, 54, currently Aetna’s president and head of Business Operations, will be appointed chief executive officer and elected to the company’s Board of Directors.
The Board intends to elect Bertolini to the additional role of chairman of the Board upon the retirement of Williams, according to Aetna.
Bertolini joined Aetna in February 2003 and held a series of roles with increasing responsibilities before being named president in July 2007. Prior to joining Aetna, Bertolini held positions with Cigna and NYLCare and had been chief executive officer of SelectCare.
Aetna said that in his full-time role as executive chairman, Williams will focus on board duties as well as Aetna’s Chairman’s Initiatives, public policy and federal regulatory strategy. Following his retirement from Aetna, Williams has agreed to provide consulting services to Aetna and the Aetna Foundation through February 2012.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Mental Health Comorbidities Affect Uptravi Prescribing for PAH
October 23rd 2024New real-world data suggest that physicians are cautious about prescribing the prostacyclin-receptor agonist Uptravi (selexipag) to pulmonary arterial hypertension (PAH) patients with mental health conditions when evidence suggests that it is best to take a proactive approach to treating PAH.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
High-Dose Eylea Shows Unique Properties in nAMD and DME | AAO 2024
October 22nd 2024A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Read More
